Prostacyclin: An inflammatory paradox.

Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best-characterized role is in the cardiovascular system, where it is released by vascular endothelial cells, serving as a potent vasodilator and inhibitor of platelet aggregation. In recent years, prostacyclin (PGI...

書目詳細資料
發表在:	Frontiers in Pharmacology
Main Authors:	Jeremiah eStitham, Charles eMidgett, Kathleen eMartin, John eHwa
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2011-05-01
主題:	Atherosclerosis Inflammation Pulmonary Fibrosis Rheumatoid arthritis Prostacyclin pulmonary hypertension
在線閱讀:	http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00024/full

相似書籍

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
由: Elizabeth Colglazier, et al.
出版: (2022-10-01)

Prostacyclin pathway vasodilators in patients with chronic thromboembolic pulmonary hypertension (CTEPH): A systemic review and meta‐analysis of randomized controlled trials
由: Weijun Li, et al.
出版: (2024-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
由: E. A. Rezukhina, et al.
出版: (2021-09-01)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
由: Akram Khan, et al.
出版: (2023-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
由: Abdullah A. Alqarni, et al.
出版: (2023-08-01)

Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey
由: Anjali Vaidya, et al.
出版: (2024-11-01)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?
由: Sylwester P. Rogula, et al.
出版: (2021-12-01)

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis
由: Khaled M. Saleh, et al.
出版: (2025-10-01)

Pericardial Effusion and Prostacyclin Analog Toxicity After Initiation of Sotatercept
由: Dany Tager, et al.
出版: (2025-07-01)

Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial
由: Sefri Noventi Sofia, et al.
出版: (2025-06-01)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
由: Agnieszka Blitek, et al.
出版: (2022-08-01)

Outpatient Intravenous Dobutamine as Right Ventricular Support During Inhaled Prostacyclin Uptitration in Severe PH‐ILD
由: A. Kumar, et al.
出版: (2025-07-01)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
由: Raj Parikh, et al.
出版: (2022-10-01)

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
由: Shelley Shapiro, et al.
出版: (2021-10-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
由: Stephanie S. Handler, et al.
出版: (2022-07-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
由: Hardin EA, et al.
出版: (2016-11-01)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
由: Julia Timofeev, et al.
出版: (2013-03-01)

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
由: Justin J. Kochanski, et al.
出版: (2024-01-01)

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series
由: Elizabeth Colglazier, et al.
出版: (2023-07-01)

The PH‐ILD Detection tool: External validation and use in patients with ILD
由: Raj Parikh, et al.
出版: (2023-07-01)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
由: John F. Kingrey, et al.
出版: (2023-07-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
由: Pierson Richard, et al.
出版: (2002-02-01)

Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation
由: Aleksander Siniarski, et al.
出版: (2022-10-01)

Rheumatoid arthritis presenting by combined pulmonary fibrosis and emphysema with clubbing and pulmonary hypertension: A rare case report
由: Reza Basiri, et al.
出版: (2024-11-01)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
由: Vijay P. Balasubramanian, et al.
出版: (2022-01-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
由: Aparna C. Swaminathan, et al.
出版: (2024-11-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
由: Julia McSweeney, et al.
出版: (2023-04-01)

Acute myocardial infarction following inhaled treprostinil initiation
由: Bilal Alqam, et al.
出版: (2025-01-01)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
由: Şükran Yıldırım
出版: (2023-07-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
由: Masataka Kuwana, et al.
出版: (2023-01-01)

Effects Of Prostacyclın In Osteoclastıc Actıvatıon
由: Yalçın Işımer, et al.
出版: (1990-11-01)

Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
由: Davies EW, et al.
出版: (2018-06-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
由: Jenna M. Faircloth, et al.
出版: (2023-08-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
由: Jenna M. Faircloth, et al.
出版: (2023-03-01)

The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges
由: Swisher JW, et al.
出版: (2023-03-01)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
由: Mizuki Momoi, et al.
出版: (2022-01-01)

Case report: Extracorporeal life support as a successful bridge to recovery in an incident case of pulmonary arterial hypertension
由: Benjamin Pequignot, et al.
出版: (2024-02-01)

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension
由: Yoo-Jin Kim, et al.
出版: (2024-01-01)

Increased expression and catalytic activity of prostacyclin synthase after simvastatin application to human umbilical vein endothelial cells
由: Cho Sun-Ah, et al.
出版: (2020-01-01)

Prostacyclin Regulation of Allergic Inflammation
由: Kunj Patel, et al.
出版: (2022-11-01)